Clinical pharmacokinetics of alamifovir and its metabolites

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 1813-1822

  Chan, Clark ^a   Abu Raddad, Eyas ^b   Golor, Georg ^c   Watanabe, Hikari ^d   Sasaki, Akira ^d   Yeo, Kwee Poo ^a   Soon, Danny ^a   Sinha, Vikram P ^b   Flanagan, Shawn D ^b,e   He, Minxia M ^b   Wise, Stephen D ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

^c PAREXEL INTERNATIONAL   (United States)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^e LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAMIFOVIR; DRUG METABOLITE; LAMIVUDINE; PLACEBO; PRODRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG STRUCTURE; DRUG TOLERABILITY; FLATULENCE; FOOD DRUG INTERACTION; HEADACHE; HEPATITIS B VIRUS; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MULTIPLE DRUG DOSE; NAUSEA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; TANDEM MASS SPECTROMETRY; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PRODRUGS; PURINES;

EID: 20944444466     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.1813-1822.2005     Document Type: Article

References (22)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. J. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. André, F. 2000. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 18:S20-S22.
3. Coates, J. A., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
4. Cundy, K. C., P. Barditch-Crovo, R. E. Walker, A. C. Collier, D. Ebeling, J. Toole, and H. S. Jaffe. 1995. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 39:2401-2405.
5. Cundy, K. C., J. P. Shaw, and W. A. Lee. 1994. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys. Antimicrob. Agents Chemother. 38:365-368.
6. Farrell, G. C. 2000. Clinical potential of emerging new agents in hepatitis B. Drugs 60:701-710.
7. Gough, K., M. Hutchison, O. Keene, B. Byrom, S. Ellis, L. Lacey, and J. McKellar. 1995. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf. J. 29:1039-1048.
8. Hoofnagle, J. H., and A. M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
9. Kamiya, N., A. Kubota, Y. Iwase, K. Sekiya, M. Ubasawa, and S. Yuasa. 2002. Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 46:2872-2877.
10. Kane, M. A. 1996. Global status of hepatitis B immunisation. Lancet 348:696.
11. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998. A one-year trial of lamivudine for chronic hepatitis. N. Engl. J. Med. 339: 61-68.
12. Liaw, Y. F., N. W. Y. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, R. N. Chien, J. Dent, L. Roman, S. Edmundson, and C. L. Lai. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180.
13. Ono, S. K., N. Kato, Y. Shiratori, J. Kato, T. Goto, R. F. Schinazi, F. J. Carrilho, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107:449-455.
14. Ono-Nita, S. K., N. Kato, Y. Shiratori, F. J. Carrilho, and M. Omata. 2002. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob. Agents Chemother. 46:2602-2605.
15. Rule, A. D., H. M. Gussak, G. R. Pond, E. J. Bergstralh, M. D. Stegall, F. G. Cosio, and T. S. Larson. 2004. Measured and estimated GFR in healthy potential kidney donors. Am. J. Kidney Dis. 43:112-119.
16. Shapiro, C. N. 1993. Epidemiology of hepatitis B. Pediatr. Infect. Dis. J. 12: 433-437.
17. Shaw, J. P., M. S. Louie, V. V. Krishnamurthy, M. N. Arimilli, R. J. Jones, A. M. Bidgood, W. A. Lee, and K. C. Cundy. 1997. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 25: 362-366.
18. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and D. L. Tyrrell. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
19. Torresi, J., and S. Locarnini. 2000. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 118:S83-S103.
20. Wong, D. K. H., A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Detsky, and J. Heathcote. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119:312-323.
21. Yuen, G. J., D. M. Morris, P. K. Mydlow, S. Haidar, S. T. Hall, and E. K. Hussey. 1995. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35:1174-1180.
22. Zar, J. H. 1999. Multisample hypotheses: the analysis of variance, p. 177-207. In T. Ryu and S. L. Snavely (ed.). Biostatistical analysis, 4th ed. Prentice-Hall, Upper Saddle River, N.J.